FPABIO
Updates & Milestones
FPAbio continues to advance the Novelet™ adjustable intubation stylet through clinician engagement, military medicine collaboration, and national innovation forums. Recent and upcoming milestones include:
UPCOMING CLINICAL PRESENTATION
Brooke Army Medical Center (BAMC)
FPAbio will present the Novelet™ to anesthesiologists and CRNAs at Brooke Army Medical Center (BAMC), one of the U.S. Department of Defense’s premier military treatment facilities. This session will focus on emergency and austere airway management, first-pass success, and real-time tube control in high-risk scenarios.
Significance:
Direct engagement with frontline military anesthesiology clinicians to evaluate real-world performance and operational relevance.
LETTER OF INTEREST
Major Kelly Ivins O’Keefe, USAF
FPAbio has received a formal Letter of Interest from Kelly Ivins O’Keefe, expressing interest in the Novelet™ for military and emergency airway applications.
Significance:
Independent validation from a senior military medical officer, reinforcing the relevance of Novelet™ to combat casualty care and operational medicine.
TECH TUESDAY PRESENTATION
SOFWERX
FPAbio has been selected to present at SOFWERX Tech Tuesday, a technology-scouting forum supporting U.S. Special Operations Command (USSOCOM).
Significance:
Exposure to defense stakeholders focused on deployable, field-ready medical technologies with clear dual-use potential.
ORAL PRESENTATION
TechConnect World Innovation Conference
FPAbio will deliver an in-person oral presentation at TechConnect World Innovation Conference & Expo in Raleigh, NC.
Significance:
Oral presentations are selectively awarded to technologies with strong technical merit and commercialization potential. This venue connects federal laboratories, DoD stakeholders, and industry partners evaluating scalable, real-world solutions.
ACCEPTANCE INTO
TEDCO’s NSF Sbir/STTR proposal lab
Significance:
Acceptance into TEDCO’s NSF SBIR/STTR Proposal Lab reflects FPAbio’s alignment with the National Science Foundation’s standards for technical merit, innovation, and commercial potential. The program is selective and designed for companies developing high-impact technologies that require disciplined technical validation and a credible path to commercialization.
Participation provides FPAbio with structured, expert-guided preparation for federal SBIR/STTR funding—strengthening our ability to pursue non-dilutive capital, engage rigorously with federal review criteria, and execute a repeatable proposal strategy applicable across NSF, DoD, NIH, and other agencies. This milestone supports FPAbio’s broader objective of advancing clinically relevant, deployable medical technologies through well-governed R&D and commercialization pathways.